Longeveron Inc.

Phase 2 AI-extracted

laromestrocel (LOMECEL-B®)

hypoplastic left heart syndrome (HLHS)

Countdown

55days

Phase 2 readout · Aug 31, 2026

What's at stake Phase 2 trial results for laromestrocel (LOMECEL-B®) in hypoplastic left heart syndrome (HLHS) are due Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 14h ago

“Top-line results from the randomized, controlled Phase 2b ELPIS II clinical trial are anticipated in August 2026.”

Add to calendar Post on X Reddit

Provenance